Publication: A multi-stakeholder approach in optimising patients' needs in the benefit assessment process of new metastatic breast cancer treatments.
Loading...
Identifiers
Date
2020-04-24
Authors
Cardoso, Fatima
Wilking, Nils
Bernardini, Renato
Biganzoli, Laura
Espin, Jaime
Miikkulainen, Kaisa
Schuurman, Susanne
Spence, Danielle
Spitz, Sabine
Ujupan, Sonia
Advisors
Journal Title
Journal ISSN
Volume Title
Publisher
Churchill Livingstone
Abstract
There is a growing understanding as science evolves that different cancer types require different approaches to treatment evaluation, especially in the metastatic stages. The introduction of new metastatic breast cancer (MBC) treatments may be hindered by several elements, including the availability of relevant evidence related to disease-specific outcomes, the benefit assessment process around the evaluation of the clinical benefit and the patients' need of new treatments. The Steering Committee (SC) found that not all issues relevant to MBC patients are consistently considered in the current benefit assessment process of new treatments. Among these are overall survival, time-to-event endpoints (e.g. progression-free survival), patients' priorities, burden of disease, MBC-specific quality of life, value in delaying chemotherapy, route of administration, side effects and toxicities, treatment adherence and the benefit of real-world evidence. This paper calls on decision makers to (1) Include MBC-specific patient priorities and outcomes in the overall benefit assessments of new MBC treatments; (2) Enhance multi-stakeholder collaboration in order to improve MBC patient outcomes.
Description
MeSH Terms
Breast Neoplasms
Decision Making
Health Planning
Humans
Patient Preference
Policy
Quality of Life
Stakeholder Participation
Technology Assessment, Biomedical
Decision Making
Health Planning
Humans
Patient Preference
Policy
Quality of Life
Stakeholder Participation
Technology Assessment, Biomedical
DeCS Terms
Calidad de vida
Evaluación de la tecnología
Biomédica
Humanos
Neoplasias de la mama
Participación de los interesados
Planificación en salud
Políticas
Prioridad del paciente
Toma de decisiones
Evaluación de la tecnología
Biomédica
Humanos
Neoplasias de la mama
Participación de los interesados
Planificación en salud
Políticas
Prioridad del paciente
Toma de decisiones
CIE Terms
Keywords
Health technology assessment, Metastatic breast cancer, Patient preferences, Policy, Stakeholders, Treatment benefit
Citation
Cardoso F, Wilking N, Bernardini R, Biganzoli L, Espin J, Miikkulainen K, et al. A multi-stakeholder approach in optimising patients' needs in the benefit assessment process of new metastatic breast cancer treatments. Breast. 2020 Aug;52:78-87.